1. Report Introduction 2. Bile Duct Cancer (Cholangiocarcinoma) Overview 3. Pipeline Therapeutics • An Overview of Pipeline Products for Bile Duct Cancer (Cholangiocarcinoma) 4. Comparative Analysis 5. Products in Clinical Stage 5.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 6. Products in Pre-Clinical and Discovery Stage 6.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities 7. Therapeutic Assessment • Assessment by Route of Administration • Assessment by Stage and Route of Administration • Assessment by Molecule Type • Assessment by Stage and Molecule Type 8. Inactive Products 8.1 Drug Name : Company Name • Product Description • Research and Development • Product Development Activities Appendix Report Methodology Consulting Services Disclaimer About DelveInsight

Table 1: Total Products for Bile Duct Cancer (Cholangiocarcinoma) Table 2: Products in Clinical Stage Table 3: Products in Non-clinical Stage Table 4: Assessment by Route of Administration Table 5: Assessment by Stage and Route of Administration Table 6: Assessment by Molecule Type Table 7: Assessment by Stage and Molecule Type Table 8: Inactive Products Figure 1: Total Products for Bile Duct Cancer (Cholangiocarcinoma) Figure 2: Products in Clinical Stage Figure 3: Products in Non-clinical Stage Figure 4: Assessment by Route of Administration Figure 5: Assessment by Stage and Route of Administration Figure 6: Assessment by Molecule Type Figure 7: Assessment by Stage and Molecule Type Figure 8: Inactive Products

PCI Biotech AS Delcath Systems Inc. Merck Sharp & Dohme Corp. Aslan Pharmaceuticals Kosan Biosciences Leap Therapeutics 4SC AG Adgero Biopharmaceuticals Inc Agios Pharmaceuticals Inc Ariad Pharmaceuticals Inc ArQule Inc Array BioPharma Inc Arrien Pharmaceuticals LLC Aslan Pharmaceuticals Pte Ltd Bavarian Nordic A/S Bayer AG BeiGene Ltd Blueprint Medicines Corp Boehringer Ingelheim GmbH Boston Biomedical Inc & list continues...